Cash Capital has returned for OnQuality Pharmaceuticals’s latest round, having already participated in a $15m series A in 2019.

OnQuality Pharmaceuticals, a US-based developer of drugs to counteract chemotherapy side effects, secured $20m in series A-plus financing today from investors including Cash Capital, the investment arm of Chinese Academy of Sciences.
Sinovation Ventures, Shiyu Capital, Matrix Partners China, BioTrack Capital and Frees Fund also took part, as did unnamed investors.
Founded in 2018, OnQuality is developing treatments drugs for patients undergoing cancer therapy that lessen side effects associated with current medications.
It will put the money…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in